Careers

  • Machine Learning Engineer

    VANCOUVER, BC (OR REMOTE) / 2+ YRS PROFESSIONAL EXPERIENCE

    Small molecule drug discovery is one of the most exciting open problems in machine learning. Traditional approaches require over ten years and two billion dollars to develop a new pharmaceutical, and their reliance on trial-and-error calls out for better predictive and generative models. The existent datasets are large enough to benefit from sophisticated deep learning…

    Learn More: Machine Learning Engineer

  • Cheminformatician

    VANCOUVER, BC (OR REMOTE) / 2+ YRS PROFESSIONAL EXPERIENCE

    Variational AI is radically accelerating the development of promising drug candidates by integrating chemistry and pharmacology expertise with the state-of-the-art in machine learning. Traditional approaches to small molecule drug discovery require over ten years and two billion dollars, and their reliance on trial-and-error calls out for better predictive and generative models. The current industry standard…

    Learn More: Cheminformatician

  • Machine Learning Scientist

    VANCOUVER, BC (OR REMOTE) / 3+ YEARS EXPERIENCE

    Small molecule drug discovery is one of the most exciting open problems in machine learning. Traditional approaches require over ten years and two billion dollars to develop a new pharmaceutical, and their reliance on trial-and-error calls out for better predictive and generative models. The existent datasets are large enough to benefit from sophisticated deep learning…

    Learn More: Machine Learning Scientist

At Variational AI we are guided by trying to answer the question: how many life-saving blockbuster drugs exist in chemical space just waiting to be discovered?

But finding the right molecules that could become drugs is impossible using the screening and brute-force methods the drug industry uses today. Chemical space is simply too vast. Our answer is to leverage a powerful new form of machine learning known as generative AI to free us from reliance on screening and libraries, both experimental and virtual, to generate de novo molecules with all the optimized properties to discover efficacious, safe, and synthesizable small molecule therapeutics in a fraction of the time and cost as the status quo.

Our answer is not screen molecules, but to create them. We have built a platform to do this called Enki, and we are starting with oncology.

Our Approach